Fourth quarter revenue increased 6% to $63.7 billion Fourth quarter GAAP****1 diluted EPS increased 70% to $1.70 Excluding a one-time positive impact of $0.31 from the recognition of the IEEPA tariff refund, fourth quarter non-GAAP diluted EPS…
-
Fourth quarter revenue increased 6% to $63.7 billion
-
Fourth quarter GAAP****1 diluted EPS increased 70% to $1.70
-
Excluding a one-time positive impact of $0.31 from the recognition of the IEEPA tariff refund, fourth quarter non-GAAP diluted EPS increased 25% to $2.60, with reported fourth quarter non-GAAP diluted EPS increasing 40% to $2.91
-
For fiscal year 2026, excluding the IEEPA tariff refund recognition, non-GAAP diluted EPS increased 33% to $10.95, with reported non-GAAP diluted EPS increasing 37% to $11.26
-
Fiscal year 2026 operating cash flow $5.2 billion and adjusted free cash flow $5.0 billion
-
Incremental $350 million share repurchase completed, bringing fiscal year 2026 repurchase total to $1.4 billion, with $5.0 billion incremental repurchase authorization approved by board of directors
-
Cardinal Health provides fiscal year 2027 non-GAAP EPS guidance2 of 13% to 15% growth3 ($12.40 to $12.60), above the Company's long-term EPS guidance
DUBLIN, Ohio, Aug. 11, 2026 /PRNewswire
/ -- Cardinal Health (NYSE: CAH) today reported fourth quarter fiscal year 2026 revenues of $63.7 billion, an increase of 6% from the fourth quarter of fiscal year 2025. Fourth quarter GAAP operating earnings increased 70% to $729 million and GAAP diluted earnings per share (EPS) increased 70% to $1.70.
Fourth quarter non-GAAP operating earnings increased 30% to $935 million. Non-GAAP diluted EPS increased 40% to $2.91, reflecting the increase in non-GAAP earnings, including the recognition of a one-time net operating profit impact of IEEPA tariff refunds of $100 million in the GMPD segment, a lower non-GAAP effective tax rate, and a lower share count, partially offset by an increase in interest and other expense.
Fiscal year 2026 revenues were $254.2 billion, a 14% increase from fiscal year 2025. GAAP operating earnings were $2.6 billion and GAAP diluted EPS was $7.23. Non-GAAP operating earnings increased 30% to $3.6 billion, driven by segment profit increases across all five operating segments. Non-GAAP diluted EPS increased 37% to $11.26 for the year, reflecting the increase in non-GAAP operating earnings across the business, including the recognition of a one-time net operating profit impact of IEEPA tariff refunds of $100 million in the GMPD segment, a lower non-GAAP effective tax rate, and a lower share count following in-year share repurchases, partially offset by an increase in interest and other expense.
"Fiscal 2026 was a standout year for Cardinal Health and I am pleased with our strong fourth quarter results," said Jason Hollar, CEO of Cardinal Health. "The broad-based operational strength for the year, with all five of our operating segments growing profit double-digits, even before recognition of IEEPA tariff recoveries in GMPD, reflects the disciplined execution of our strategy and our investments for growth. We enter Fiscal 2027 with momentum and confidence in our ability to deliver continued shareholder value creation."
Q4 and full year FY26 summary
| | | | | | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| | Q4 FY26 | | Q4 FY25 | | Y/Y | | FY26 | | FY25 | | Y/Y |
| Revenue | $63.7 billion | | $60.2 billion | | 6 % | | $254.2 billion | | $222.6 billion | | 14 % |
| Operating earnings | $729 million | | $428 million | | 70 % | | $2.6 billion | | $2.3 billion | | 15 % |
| Non-GAAP operating earnings | $935 million | | $719 million | | 30 % | | $3.6 billion | | $2.8 billion | | 30 % |
| Net earnings attributable to Cardinal Health, Inc. | $398 million | | $239 million | | 67 % | | $1.7 billion | | $1.6 billion | | 10 % |
| Non-GAAP net earnings attributable to Cardinal Health, Inc. | $682 million | | $501 million | | 36 % | | $2.7 billion | | $2.0 billion | | 34 % |
| Effective Tax Rate | 27.9 % | | 36.9 % | | | | 21.6 % | | 25.3 % | | |
| Non-GAAP Effective Tax Rate | 22.5 % | | 26.3 % | | | | 19.0 % | | 23.3 % | | |
| Diluted EPS attributable to Cardinal Health, Inc. | $1.70 | | $1.00 | | 70 % | | $7.23 | | $6.45 | | 12 % |
| Non-GAAP diluted EPS attributable to Cardinal Health, Inc. | $2.91 | | $2.08 | | 40 % | | $11.26 | | $8.24 | | 37 % |
Segment results
Pharmaceutical and Specialty Solutions segment
| | | | | | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| | Q4 FY26 | | Q4 FY25 | | Y/Y | | FY26 | | FY25 | | Y/Y |
| Revenue | $58.8 billion | | $55.4 billion | | 6 % | | $234.8 billion | | $204.6 billion | | 15 % |
| Segment profit | $645 million | | $535 million | | 21 % | | $2.8 billion | | $2.3 billion | | 23 % |
Fourth quarter revenue for the Pharmaceutical and Specialty Solutions segment increased 6% to $58.8 billion, driven by brand and specialty pharmaceutical sales growth from existing customers.
Pharmaceutical and Specialty Solutions segment profit increased 21% to $645 million in the fourth quarter, primarily driven by contributions from brand and specialty products and positive generics program performance.
Global Medical Products and Distribution segment
| | | | | | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| | Q4 FY26 | | Q4 FY25 | | Y/Y | | FY26 | | FY25 | | Y/Y |
| Revenue | $3.1 billion | | $3.2 billion | | (2) % | | $12.7 billion | | $12.6 billion | | 1 % |
| Segment profit | $150 million | | $70 million | | N.M. | | $258 million | | $135 million | | 91 % |
Fourth quarter revenue for the Global Medical Products and Distribution segment decreased 2% from the prior year to $3.1 billion. This decrease was primarily driven by lower distribution volumes and the recognition of the expected IEEPA tariff refund repayment to customers, partially offset by Cardinal Health brand growth.
Global Medical Products and Distribution segment profit increased to $150 million in the fourth quarter, primarily driven by IEEPA tariff refunds.
Other****4
| | | | | | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| | Q4 FY26 | | Q4 FY25 | | Y/Y | | FY26 | | FY25 | | Y/Y |
| Revenue | $1.7 billion | | $1.6 billion | | 7 % | | $6.8 billion | | $5.4 billion | | 26 % |
| Segment profit | $183 million | | $160 million | | 14 % | | $707 million | | $516 million | | 37 % |
Fourth quarter revenue for Other increased 7% to $1.7 billion, driven by growth across the three operating segments: Nuclear and Precision Health Solutions, OptiFreight Logistics, and at-Home Solutions.
Other segment profit increased 14% to $183 million in the fourth quarter, driven by growth in OptiFreight Logistics and at-Home Solutions.
Fiscal year 2027 outlook****2
The company released its fiscal year 2027 outlook for non-GAAP diluted EPS of +13% to +15% growth3 ($12.40 to $12.60).
| | |
| --- | --- |
| Non-GAAP earnings per share | $12.40 to $12.60 |
| Pharmaceutical and Specialty Solutions segment: | |
| Revenue | 3% to 5% growth |
| Segment profit | 8% to 11% growth |
| Global Medical Products and Distribution segment: | |
| Revenue | 2% to 4% growth |
| Segment profit | $200 million to $220 million |
| Other (NPHS, at-Home Solutions, OptiFreight Logistics): | |
| Revenue | 11% to 13% growth |
| Segment profit | 15% to 18% growth |
| Interest and other | $240 million to $290 million |
| Non-GAAP effective tax rate | 19.0% to 20.0% |
| Diluted weighted average shares outstanding | ~233 million |
| Share repurchases | ~$1 billion |
| Capital Expenditures | ~$700 million |
| Non-GAAP adjusted free cash flow | $3.5 billion to $4.0 billion |
Financial guidance for fiscal year 2027 reflects the estimated impact of the Company's recently completed tuck-in acquisition of Strive Medical and the announced tuck-in acquisition of the Diabetes Health business of AdaptHealth.
Recent highlights
-
Cardinal Health recently completed an additional $350 million accelerated share repurchase program, bringing year-to-date share repurchases in fiscal year 2026 to $1.4 billion.
-
Cardinal Health Board of Directors approved a $5.0 billion increase to the share repurchase program, bringing the total share repurchase authorization to $6.4 billion as of August 2026
-
Cardinal Health announces simplification of credit facilities with new $4.0 billion revolving credit facility replacing three historic facilities
-
Cardinal Health announces long-term renewal of wholesaler distribution contract with Kroger
-
New distribution center in Indianapolis set to open in 2027 featuring advanced robotics and automation, adding capacity and enabling operational flexibility
-
Cardinal Health Board of Directors declared a regular quarterly dividend of $0.5158 per share, payable on October 15, 2026, to shareholders of record on October 1, 2026
Webcast
Cardinal Health will host a webcast today at 8:30 a.m. ET to discuss fourth quarter and full year results. To access the webcast and corresponding slide presentation, go to the Investor Relations page at ir.cardinalhealth.com
. No access code is required.
Presentation slides and a webcast replay will be available on the Investor Relations page for 12 months.